Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Agilent Announces AssayMAP Bravo Protein Sample Prep Workbench 4.0


Agilent Technologies Inc. (NYSE: A) today announced the release of the AssayMAP Bravo Protein Sample Prep Workbench 4.0 software. This release adds 21 CFR Part 11 compliance-enabling features that allow AssayMAP Bravo-based automated sample preparation in workflows across the biopharma drug development process.

The requirement for labs to use instruments that comply with regulatory guidelines such as 21 CFR Part 11 or have the option of turning on compliance-enabling software features is moving to earlier stages of the drug development process. The AssayMAP Workbench 4.0 addresses these requirements and facilitates the seamless transfer of assays along the entire drug development process, including moving from non-compliant to compliant laboratories.

AssayMAP Workbench 4.0 simplifies the documentation required in regulated laboratories and desired in non-regulated labs by providing the option to generate reports that capture sample prep workflow data. The new AssayMAP software enables novice users to use the system with minimal training by providing a walk-up operation option.

“The addition of compliance enabling features, walk-up capabilities, and report generation provide our customers added value across the entire biopharma drug development process,” said Lars Kristiansen, general manager of Agilent’s Automation Solutions business. “These enhancements align with our focus to provide new solutions to our biopharma partners that enable them to bring biotherapeutics to market faster and more cost-effectively.”

AssayMAP Workbench 4.0 also expands software support for the recently released AssayMAP large-capacity cartridges. These cartridges enhance the ability of biopharma labs to analyze biotherapeutic critical quality attributes and enable more complete automation of sample prep workflows.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005435/en/

Agilent Technologies Inc. Stock

€138.82
-0.520%
Agilent Technologies Inc. shows a slight decrease today, losing -€0.720 (-0.520%) compared to yesterday.
Our community is currently high on Agilent Technologies Inc. with 10 Buy predictions and 3 Sell predictions.
On the other hand, the target price of 133 € is below the current price of 138.82 € for Agilent Technologies Inc., so the potential is actually -4.19%.
Like: 0
Share
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments